The Claim

Serum levels of TSH-binding inhibitory immunoglobulin (TBII) and thyroid-stimulating antibodies (TSAb) at the time of drug discontinuation are significantly lower in patients with Graves' disease who achieve long-term remission than in those who relapse, but the overlap in levels between the two groups is too broad to enable reliable individual outcome prediction.

Source: Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
39score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Correlation
1 study reviewed
In plain English

In patients with Graves' disease, those who remain in remission after stopping medication have lower levels of TBII and TSAb antibodies at the time of discontinuation than those who relapse, but the range of antibody levels overlaps so much that it cannot reliably predict which individuals will relapse.

See the scientific wording

Serum levels of TSH-binding inhibitory immunoglobulin (TBII) and thyroid-stimulating antibodies (TSAb) at the time of drug discontinuation are significantly lower in patients with Graves' disease who achieve long-term remission compared to those who relapse, but their overlap is too broad to reliably predict individual outcomes.

Why this might work

When the immune system stops producing high levels of antibodies that force the thyroid to overwork, the gland can return to normal function. If these antibodies drop low enough before stopping treatment, the thyroid stays stable. If they stay high, the thyroid gets overstimulated again and disease returns.

Supported mechanismbased on 1 study

What the research says

1 study

  1. Study: Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease.

    When people with Graves' disease stop their medicine, those who stay healthy tend to have lower levels of certain antibodies, but lots of people with high levels also stay healthy — so doctors can't use these antibody levels to tell who will relapse.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.